
- Insmed (INSM) shows strong technical momentum, hitting a new 52-week high on Aug. 18.
- INSM has a 100% “Buy” opinion from Barchart with impressive recent gains.
- Revenue is projected to grow nearly 29% this year and 126% next year, with earnings growth expected to accelerate in 2026.
- Wall Street analysts are mostly bullish, but there is a wide range of price targets on INSM here.